Contrast nephropathy is a common cause of iatrogenic acute renal failure. Its incidence rises with the growing use of intra-arterial contrast in diagnostic and interventional procedures. Aim of the present review is to summarize the knowledge about pathophysiology and prevention. Nephrotoxicity is related to osmolality, dose and route of the contrast and only occurs in synergy with other factors, such as previous renal impairment and cardiovascular disease. With an interplay of these factors, contrast nephropathy has an impact on morbidity and mortality. Pathophysiological mechanisms are intrarenal vasoconstriction, leading to medullary ischemia, direct cytotoxicity, oxidative tissue damage and apoptosis. Several measures are of proven benefit in patients at risk. Among them are discontinuation of potentially nephrotoxic drugs, hydration, preferably with isotonic sodium bicarbonate, use of low osmolal contrast, oral or intravenous N-acetylcysteine and intravenous theophylline. In patients with severe cardiac and renal dysfunction undergoing cardiac interventions, periprocedural hemofiltration may be considered.
RichM.W., CreceliusC.A.Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med1990; 150: 1237–42.
9.
HizohI., StraterJ., SchickC.S., KublerW., HallerC.Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: Role of hypertonicity. Nephrol Dial Transplant1998; 13: 911–8.
10.
BarrettB.J., CarlisleE.J.Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology1993; 188: 171–8.
11.
RudnickM.R., GoldfarbS., WexlerL., LudbrookP.A., MurphyM.J., HalpernE.F., HillJ.A., WinnifordM., CohenM.B., VanFossenD.B.Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Coop Study. Kidney Int1995; 47: 254–61.
12.
AspelinP., AubryP., FranssonS.G., StrasserR., WillenbrockR., BergK.J.Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med2003; 348: 491–9.
13.
ManskeC.L., SprafkaJ.M., StronyJ.T., WangY.Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med1990; 89: 615–20.
HuberW., SchipekC., IlgmannK., PageM., HennigM., WackerA., SchweigartU., LutilskyL., ValinaC., SeyfarthM., SchomigA., ClassenM.Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol2003; 91: 1157–62.
16.
Diaz-SandovalL.J., KosowskyB.D., LosordoD.W.Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol2002; 89: 356–8.
17.
MuellerC., BuerkleG., BuettnerH.J., PetersenJ., PerruchoudA.P., ErikssonU., MarschS., RoskammH.Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med2002; 162: 329–36.
18.
AbizaidA.S., ClarkC.E., MintzG.S., DosaS., PopmaJ.J., PichardA.D., SatlerL.F., HarveyM., KentK.M., LeonM.B.Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol1999; 83: 260–3.
19.
ArakawaK., SuzukiH., NaitohM., MatsumotoA., HayashiK., MatsudaH., IchiharaA., KubotaE., SarutaT.Role of adenosine in the renal responses to contrast medium. Kidney Int1996; 49: 1199–206.
20.
ErleyC.M., HeyneN., RossmeierS., VogelT., RislerT., OsswaldH.Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int1998; 67(suppl): S192–4.
21.
RussoD., MinutoloR., CianciarusoB., MemoliB., ConteG., De NicolaL.Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol1995; 6: 1451–8.
22.
ErleyC.M., HeyneN., BurgertK., LangankeJ., RislerT., OsswaldH.Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol1997; 8: 1125–32.
NishiyamaA., EdwardW., InschoE.W., NavarL.G.Interactions of adenosine A1 and A2a receptors on renal microvascular reactivityAm J Physiol Renal Physiol2001; 280: F406–14.
31.
LeeH.T., EmalaC.W.Protective effects of renal ischemic preconditioning and adenosine pre-treatment: Role of A1 and A3 receptors. Am J Physiol Renal Physiol2000; 278: F380–F387.
32.
HeymanS.N., ClarkB.A., KaiserN., SpokesK., RosenS., BrezisM., EpsteinF.H.Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol1992; 3: 58–65.
33.
MurphyM.E., TublinM.E., LiS.Influence of contrast media on the response of rat renal arteries to endothelin and nitric oxide: Influence of contrast media. Invest Radiol1998; 33: 356–65.
34.
BakrisG.L., LassN., GaberA.O., JonesJ.D., BurnettJ.C.Jr.. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol1990; 58: F115–20.
35.
KatholiR.E., WoodsW.T.Jr., TaylorG.J., DeitrickC.L., WomackK.A., KatholiC.R., McCannW.P.Oxygen free radicals and contrast nephropathy. Am J Kidney Dis1998; 32: 64–71.
36.
YoshiokaT., FogoA., BeckmanJ.K.Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int1992; 41: 1008–15.
37.
ZagerR.A., JohnsonA.C., HansonS.Y.Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kidney Int2003; 64: 128–39.
38.
WelchW.J., TojoA., WilcoxC.S.Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol2000; 278: F769–76.
39.
MertenG.J., BurgessW.P., GrayL.V., HollemanJ.H., RoushT.S., KowalchukG.J., BersinR.M., Van MooreA., SimontonCA3rd, RittaseR.A., NortonH.J., KennedyT.P.Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA2004; 29: 2328–34.
SolomonR., WernerC., MannD., D'EliaJ., SilvaP.Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med1994; 331: 1416–20.
50.
TrivediH.S., MooreH., NasrS., AggerwalK., AgrawalA., goelP., HewettJ.A randomised prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract2003: 93: C29–34.
51.
TepelM., van der GietM., SchwarzfeldC., LauferU., LiermannD., ZidekW.Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med2000; 343: 180–4.
52.
AllaqabandS., TumuluriR., MalikA.M., GuptaA., VolkertP., ShalevY., BajwaT.K.Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv2002; 57: 279–83.
DurhamJ.D., CaputoC., DokkoJ., ZaharakisT., PahlavanM., KeltzJ., DutkaP., MarzoK., MaesakaJ.K., FishbaneS.A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int2002; 62: 2202–7.
55.
ShyuK.G., ChengJ.J., KuanP.Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol2002; 40: 1383–8.
56.
KayJ., ChowW.H., ChanT.M., LoS.K., KwokO.H., YipA., FanK., LeeC.H., LamW.F.Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA2003; 289: 553–8.
57.
BirckR., KrzossokS., MarkowetzF., SchnulleP., van der WoudeF.J., BraunC.Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet2003; 362: 598–603.
58.
BakerC.S., WraggA., KumarS., De PalmaR., BakerL.R., KnightC.J.A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol2003; 41: 2114–8.
EfratiS., DishyV., AverbukhM., BlattA., KrakoverR., WeisgartenJ., MorrowJ.D., SteinM.C., GolikA.The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int2003; 64: 2182–7.
61.
HoffmannU., FischerederM., KrugerB., DrobnikW., KramerB.K.The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol2004; 15: 407–10.
62.
ErleyC.M., DudaS.H., SchlepckowS., KoehlerJ., HuppertP.E., StrohmaierW.L., BohleA., RislerT., OsswaldH.Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int1994; 45: 1425–31.
63.
KolonkoA., WiecekA., KokotF.The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol1998; 11: 151–6.
64.
ErleyC.M., DudaS.H., RehfussD., ScholtesB., BockJ., MullerC., OsswaldH., RislerT.Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant1999; 14: 1146–9.
65.
HuberW., IlgmannK., PageM., HennigM., SchweigartU., JeschkeB., LutilskyL., WeissW., SalmhoferH., ClassenM.Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: Controlled, randomized, double-blinded study. Radiology2002; 223: 772–9.
66.
KapoorA., KumarS., GulatiS., GambhirS., SethiR.S., SinhaN.The role of theophylline in contrast-induced nephropathy: A case-control study. Nephrol Dial Transplant2002; 17: 1936–41.
67.
BaderB.D., BergerE.D., RossmannS., RislerT., ErleyC.M.Prevention of contrast media-induced acute renal failure in patients with severe impaired renal function - Theophylline versus N-acetylcysteine. J Am Soc Nephrol2002; 13(Abstract SA-P0887).
68.
ErleyC.M., HeyneN., RossmeierS., VogelT., RislerT., OsswaldH.Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int1998; 67(suppl): S192–4.
69.
WangY.X., JiaY.F., ChenK.M., MorcosS.K.Radiographic contrast media induced nephropathy: Experimental observations and the protective effect of calcium channel blockers. Br J Radiol2001; 74: 1103–8.
70.
BakrisG.L., BurnettJ.C.A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int1985; 27: 465–8.
71.
NeumayerH.H., JungeW., KufnerA., WenningA.Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: A prospective randomised clinical trial. Nephrol Dial Transplant1989; 4: 1030–6.
72.
KhouryZ., SchlichtJ.R., ComoJ., KarschnerJ.K., ShapiroA.P., MookW.J., WeberR.J.The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy1995; 15: 59–65.
73.
StevensM.A., McCulloughP.A., TobinK.J., SpeckJ.P., WestveerD.C., Guido-AllenD.A., TimmisG.C., O'NeillW.W.A prospective randomized tril of prevention measures in patients at risk for contrast nephropathy: Results of the PRINCE Study. J Am Coll Cardiol1999; 33: 403–11.
74.
GareM., HavivY.S., Ben-YehudaA., RubingerD., Bdolah-AbramT., FuchsS., GatO., PopovtzerM.M., GotsmanM.S., MosseriM.The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol1999; 34: 1682–8.
75.
BakrisG.L., LassN.A., GlockD.Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role of dopamine-1 receptors. Kidney Int1999; 56: 205–10.
76.
TumlinJ.A., WangA., MurrayP.T., MathurV.S.Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J2002; 143: 894–903.
77.
MadyoonH.Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med2001; 2(suppl 1): S26–30.
78.
KiniA.A., SharmaS.K.Managing the high-risk patient: Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med2001; 2(suppl 1): S19–25.
79.
KurnikB.R., AllgrenR.L., GenterF.C., SolomonR.J., BatesE.R., WeisbergL.S.Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis1998; 31: 674–80.
80.
GuptaR.K., KapoorA., TewariS., SinhaN., SharmaR.K.Captopril for prevention of contrast-induced nephropathy in diabetic patients: A randomised study. Indian Heart J1999; 51: 521–6.
81.
HeymanS.N., ClarkB.A., CantleyL., SpokesK., RosenS., BrezisM., EpsteinF.H.Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol1993; 28: 313–8.
82.
ClarkB.A., KimD., EpsteinF.H.Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis1997; 30: 82–6.
HalorJ.L., MorcosS.H.Endothelin antagonism and contrast nephropathy. Kidney Int2000; 58: 2239.
86.
SchindlerR., StahlC., VenzS., LudatK., KrauseW., FreiU.Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant2001; 16: 1471–4.
87.
VogtB., FerrariP., SchonholzerC., MartiH.P., MohauptM., WiederkehrM., CereghettiC., SerraA., Huynh-DoU., UehlingerD., FreyF.J.Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med2001; 111: 692–8.
88.
MarenziG., MaranaI., LauriG., AssanelliE., GraziM., CampodonicoJ., TrabattoniD., FabiocchiF., MonitorsiP., BartorelliA.L.The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med2003; 349: 1333–40.
